| 10.1 0.65 (6.88%) | 06-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 12.78 | 1-year : | 15.51 |
| Resists | First : | 10.94 | Second : | 13.27 |
| Pivot price | 10.34  |
|||
| Supports | First : | 7.17 | Second : | 5.96 |
| MAs | MA(5) : | 9.83 |
MA(20) : | 9.84 |
| MA(100) : | 7.6 |
MA(250) : | 7.15 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 27.2 |
D(3) : | 32 |
| RSI | RSI(14): 52.9 |
|||
| 52-week | High : | 13.27 | Low : | 3.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TRLV ] has closed above bottom band by 44.9%. Bollinger Bands are 88% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.14 - 10.19 | 10.19 - 10.23 |
| Low: | 9.11 - 9.16 | 9.16 - 9.21 |
| Close: | 10.01 - 10.1 | 10.1 - 10.18 |
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with established medical marijuana operations in Florida, Georgia, Pennsylvania, and West Virginia.
Sun, 21 Jun 2026
Top Trulieve Cannabis (TRLV) Competitors 2026 - MarketBeat
Fri, 19 Jun 2026
Jim Cramer on Trulieve Cannabis: “I Think It’s a Terrific Spec” - Insider Monkey
Wed, 17 Jun 2026
TRLV SEC Filings - Trulieve Cannabis Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Wed, 17 Jun 2026
Total revenue of Trulieve Cannabis Corp. Subordinate Voting Shares – NYSE:TRLV - TradingView
Tue, 16 Jun 2026
Trulieve Cannabis Corp. Subordinate Voting Shares (NYSE:TRLV) Stock Quote - The Chronicle-Journal
Sat, 13 Jun 2026
Trulieve Cannabis Corp. (TRLV) - Zacks Investment Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 170 (M) |
| Shares Float | 166 (M) |
| Held by Insiders | 4.1 (%) |
| Held by Institutions | 11 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -0.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.07 |
| Profit Margin | -7 % |
| Operating Margin | 12.3 % |
| Return on Assets (ttm) | 3.2 % |
| Return on Equity (ttm) | -6.9 % |
| Qtrly Rev. Growth | -3.8 % |
| Gross Profit (p.s.) | 4.1 |
| Sales Per Share | 6.88 |
| EBITDA (p.s.) | 1.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 277 (M) |
| Levered Free Cash Flow | 201 (M) |
| PE Ratio | -25.25 |
| PEG Ratio | 0 |
| Price to Book value | 1.66 |
| Price to Sales | 1.46 |
| Price to Cash Flow | 6.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|